Tower Research Capital LLC TRC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 4,368 shares of the life sciences company’s stock, valued at approximately $1,220,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. Janney Montgomery Scott LLC lifted its holdings in shares of Illumina by 10.0% during the 2nd quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock worth $6,579,000 after acquiring an additional 2,141 shares during the last quarter. Eqis Capital Management Inc. lifted its holdings in shares of Illumina by 40.7% during the 2nd quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock worth $2,702,000 after acquiring an additional 2,797 shares during the last quarter. Welch & Forbes LLC lifted its holdings in shares of Illumina by 60.0% during the 2nd quarter. Welch & Forbes LLC now owns 1,533 shares of the life sciences company’s stock worth $428,000 after acquiring an additional 575 shares during the last quarter. Standard Life Aberdeen plc lifted its holdings in shares of Illumina by 31.1% during the 2nd quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after acquiring an additional 8,199 shares during the last quarter. Finally, Waters Parkerson & CO. LLC bought a new stake in shares of Illumina during the 2nd quarter worth $223,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

A number of research firms have recently issued reports on ILMN. Barclays lifted their price objective on shares of Illumina from $300.00 to $350.00 and gave the stock an “overweight” rating in a report on Tuesday, July 31st. JPMorgan Chase & Co. lifted their price objective on shares of Illumina to $350.00 and gave the stock an “overweight” rating in a report on Tuesday, July 31st. Cowen lifted their price objective on shares of Illumina from $275.00 to $315.00 and gave the stock an “outperform” rating in a report on Tuesday, July 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $350.00 price objective on shares of Illumina in a report on Tuesday, July 31st. Finally, Bank of America lifted their price objective on shares of Illumina from $345.00 to $370.00 and gave the stock a “buy” rating in a report on Tuesday, July 31st. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. Illumina presently has an average rating of “Buy” and a consensus target price of $308.25.

In other Illumina news, Director Robert S. Epstein sold 500 shares of the company’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $288.45, for a total value of $144,225.00. Following the sale, the director now owns 6,639 shares in the company, valued at $1,915,019.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mostafa Ronaghi sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $288.89, for a total transaction of $2,166,675.00. Following the completion of the sale, the senior vice president now owns 78,496 shares in the company, valued at approximately $22,676,709.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,837 shares of company stock worth $14,939,513. Corporate insiders own 0.54% of the company’s stock.

Shares of NASDAQ ILMN opened at $353.12 on Monday. Illumina, Inc. has a 1 year low of $196.00 and a 1 year high of $357.93. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. The stock has a market cap of $51.42 billion, a P/E ratio of 88.28, a P/E/G ratio of 2.90 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.32. The company had revenue of $830.00 million for the quarter, compared to analysts’ expectations of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. Illumina’s quarterly revenue was up 25.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.82 earnings per share. equities analysts predict that Illumina, Inc. will post 5.46 EPS for the current fiscal year.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: How to Profit and Limit Losses With Stop Orders

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.